Zoliflodacin shows promise as single-dose treatment for gonorrhea
A Phase III trial has demonstrated that zoliflodacin – a single-dose oral antibiotic – is highly effective against drug‐resistant gonorrhea, offering an innovative solution to a mounting public health threat. The encouraging results suggest a potential game‐changer in the fight against antibiotic-resistant infections.
#healthcare #pharmaceuticals #publichealth #drugdevelopment
Saturday, December 13, 2025, 8:21 pm / permalink 16937 / 2 stories in 2 months
Adding Tucatinib to First-line Maintenance Therapy Delayed Disease Progression in HER2-positive Metastatic Breast Cancer in HER2CLIMB-05 Trial / American Association for Cancer Research
Kathleen Medora / aacr - Benefit was seen across all subgroups, including in patients with brain metastasis SAN ANTONIO – Adding tucatinib (Tukysa) to first-line maintenance therapy with trastuzumab (Herceptin) and pertuzumab (Perjeta) delayed disease progression in patients with…
#healthcare #pharmaceuticals #drugdevelopment
Saturday, December 13, 2025, 4:21 am / permalink 16917 / 6 stories in 2 months
Sacituzumab govitecan-hziy led to similar progression-free survival as standard of care for some breast cancers: Trial / Medical Express
medicalxpress - Patients with hormone receptor (HR)-positive, HER2-negative advanced breast cancers had similar progression-free survival (PFS) whether they were treated with sacituzumab govitecan-hziy (Trodelvy) or standard-of-care chemotherapy as the first treatment af…
#healthcare #pharmaceuticals #drugdevelopment
Saturday, December 13, 2025, 1:21 am / permalink 16912 / 5 stories in 2 months